Seoulin Bioscience Co.Ltd (038070) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.007x

Based on the latest financial reports, Seoulin Bioscience Co.Ltd (038070) has a cash flow conversion efficiency ratio of 0.007x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩631.76 Million ≈ $428.14K USD) by net assets (₩86.05 Billion ≈ $58.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Seoulin Bioscience Co.Ltd balance sheet independence to measure how much of total assets are equity-financed.

Seoulin Bioscience Co.Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Seoulin Bioscience Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Seoulin Bioscience Co.Ltd to evaluate the quality of earnings relative to operating cash generation.

Seoulin Bioscience Co.Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Seoulin Bioscience Co.Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
eMnet Inc KQ:123570	-0.022x
FIGENE CAPITAL SA ZY 1 F:20X	N/A
A SPAC III Acquisition Corp. Class A Ordinary Shares NASDAQ:ASPC	-0.056x
Actuate Therapeutics, Inc. Common stock NASDAQ:ACTU	-0.611x
Desane Group Holdings Ltd AU:DGH	0.000x
Pop Culture Group Co Ltd NASDAQ:CPOP	-0.003x
Bliss Properti Indonesia Tbk PT JK:POSA	-0.004x
Econframe Bhd KLSE:0227	0.041x

Annual Cash Flow Conversion Efficiency for Seoulin Bioscience Co.Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Seoulin Bioscience Co.Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Seoulin Bioscience Co.Ltd market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩86.05 Billion ≈ $58.32 Million	₩4.76 Billion ≈ $3.23 Million	0.055x	+200.62%
2024-12-31	₩83.89 Billion ≈ $56.85 Million	₩-4.61 Billion ≈ $-3.13 Million	-0.055x	-590.65%
2023-12-31	₩83.06 Billion ≈ $56.29 Million	₩930.57 Million ≈ $630.63K	0.011x	+121.55%
2022-12-31	₩83.79 Billion ≈ $56.78 Million	₩-4.36 Billion ≈ $-2.95 Million	-0.052x	-143.64%
2021-12-31	₩74.86 Billion ≈ $50.73 Million	₩8.92 Billion ≈ $6.04 Million	0.119x	+93.73%
2020-12-31	₩59.92 Billion ≈ $40.61 Million	₩3.68 Billion ≈ $2.50 Million	0.061x	-49.85%
2019-12-31	₩59.71 Billion ≈ $40.46 Million	₩7.32 Billion ≈ $4.96 Million	0.123x	+57.79%
2018-12-31	₩53.72 Billion ≈ $36.40 Million	₩4.17 Billion ≈ $2.83 Million	0.078x	+207.51%
2017-12-31	₩51.49 Billion ≈ $34.90 Million	₩1.30 Billion ≈ $881.84K	0.025x	-55.42%
2016-12-31	₩48.60 Billion ≈ $32.94 Million	₩2.76 Billion ≈ $1.87 Million	0.057x	-37.62%
2015-12-31	₩45.30 Billion ≈ $30.70 Million	₩4.12 Billion ≈ $2.79 Million	0.091x	+43.12%
2014-12-31	₩43.14 Billion ≈ $29.24 Million	₩2.74 Billion ≈ $1.86 Million	0.063x	-46.57%
2013-12-31	₩41.57 Billion ≈ $28.17 Million	₩4.94 Billion ≈ $3.35 Million	0.119x	--

About Seoulin Bioscience Co.Ltd

KQ:038070 Korea Biotechnology

Market Cap

$24.62 Million

₩36.32 Billion KRW

Market Cap Rank

#24382 Global

#1715 in Korea

Share Price

₩4115.00

Change (1 day)

+0.00%

52-Week Range

₩4010.00 - ₩7270.00

All Time High

₩36786.63